First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort

被引：1

作者：

Yang, J. C-H. ^{[1
,2
]}

Kobayashi, K. ^{[3
]}

Chewaskulyong, B. ^{[4
]}

Tran, T. V. ^{[5
]}

Biswas, B. ^{[6
]}

Lee, K. H. ^{[7
]}

Feng, P-H. ^{[8
]}

Pham, X. D. ^{[9
]}

Yao, Y. ^{[10
]}

Kuyama, S. ^{[11
]}

Bing, J. Y. Tan Chun ^{[12
]}

Bhise, R. ^{[13
,14
]}

Ahn, M-J. ^{[15
]}

Sriuranpong, V. ^{[16
,17
]}

Li, R. K. ^{[18
]}

Monterroso, E. Armenteros ^{[19
]}

Barrett, K. ^{[20
]}

Albayaty, M. ^{[21
]}

Cheng, Y. ^{[22
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

[2] Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan

[3] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan

[4] Chiang Mai Univ, Dept Med, Chiang Mai, Muang, Thailand

[5] Univ Med Ctr, Dept Chemotherapy, Ho Chi Minh City, Vietnam

[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India

[7] Chungbuk Natl Univ, Dept Internal Med, Cheongju, South Korea

[8] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Taipei, Taiwan

[9] HCMC Oncol Hosp, Dept Med Oncol, Ho Chi Minh City, Vietnam

[10] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Oncol, Xian, Peoples R China

[11] Natl Hosp Org Iwakuni Clin Ctr, Dept Resp Med, Iwakuni, Japan

[12] Cebu Doctors Univ Hosp, Dept Internal Med, Cebu, Philippines

[13] JN Med Coll, Dept Med Oncol, Belagavi, India

[14] KLES Dr Prabhakar Kore Hosp & MRC, Belagavi, India

[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[16] Chulalongkorn Univ, Fac Med, Div Med Oncol, Bangkok, Thailand

[17] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[18] St Lukes Med Ctr, Inst Canc, Quezon City, Philippines

[19] AstraZeneca, Oncol R&D, Late Stage Dev, Barcelona, Spain

[20] AstraZeneca, Oncol R&D, Late Stage Dev, Biometr, Cambridge, England

[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England

[22] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

630MO

引用

页码：S1635 / S1636

页数：3

共 50 条

[21] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset
Cho, B. C.
Chewaskulyong, B.
Lee, K. H.
Dechaphunkul, A.
Sriuranpong, V.
Imamura, F.
Ohe, Y.
Nogami, N.
Kurata, T.
Okamoto, I.
Zhou, C.
Cheng, Y.
Cho, E. K.
Jye, V. P.
Lee, J-S.
Mann, H.
Saggese, M.
Reungwetwattana, T.
ANNALS OF ONCOLOGY, 2017, 28 : 190 - 190
[22] Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
Assya Akli
Nicolas Girard
Vincent Fallet
Gaelle Rousseau-Bussac
Valérie Gounant
Sylvie Friard
Jean Trédaniel
Cécile Dujon
Marie Wislez
Boris Duchemann
Etienne Giroux-Leprieur
Targeted Oncology, 2022, 17 : 675 - 682
[23] Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (14, 1070, 2023)
Chmielecki, Juliann
Gray, Jhanelle E.
Cheng, Ying
Ohe, Yuichiro
Imamura, Fumio
Cho, Byoung Chul
Lin, Meng-Chih
Majem, Margarita
Shah, Riyaz
Rukazenkov, Yuri
Todd, Alexander
Markovets, Aleksandra
Barrett, J. Carl
Hartmaier, Ryan J.
Ramalingam, Suresh S.
NATURE COMMUNICATIONS, 2023, 14 (01)
[24] Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
Akli, Assya
Girard, Nicolas
Fallet, Vincent
Rousseau-Bussac, Gaelle
Gounant, Valerie
Friard, Sylvie
Tredaniel, Jean
Dujon, Cecile
Wislez, Marie
Duchemann, Boris
Giroux-Leprieur, Etienne
TARGETED ONCOLOGY, 2022, 17 (06) : 675 - 682
[25] Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
Hori, Tomoki
Yamamoto, Kazuhiro
Ito, Takefumi
Ikushima, Shigeki
Omura, Tomohiro
Yano, Ikuko
INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 281 - 288
[26] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
Ahn, Hee Kyung
Kim, Young Saing
Kim, Eun Young
Kyung, Sun Young
Kang, Shin Myung
Cho, Eun Kyung
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
[27] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Gogishvili, M.
Melkadze, T.
Makharadze, T.
Giorgadze, D.
Dvorkin, M.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
Gessner, C.
Moreno-Jaime, B.
Passalacqua, R.
Li, S.
McGuire, K.
Quek, R. G. W.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
[28] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Gogishvili, M.
Melkadze, T.
Makharadze, T.
Giorgadze, D.
Dvorkin, M.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
Gessner, C.
Jaime, B. Moreno
Passalacqua, R.
Li, S.
McGuire, K.
Quek, R. G.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
[29] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
Aguilar-Serra, Javier
Gimeno-Ballester, Vicente
Pastor-Clerigues, Alfonso
Milara, Javier
Marti-Bonmati, Ezequiel
Trigo-Vicente, Cristina
Alos-Alminana, Manuel
Cortijo, Julio
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
[30] First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
Zhang, Hongwei
Chen, Jun
Liu, Tingting
Dang, Jun
Li, Guang
PLOS ONE, 2019, 14 (10):

← 1 2 3 4 5 →